Literature DB >> 22271395

Bisphosphonate therapy for osteoporosis: the long and short of it.

Juliet E Compston1, John P Bilezikian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22271395     DOI： 10.1002/jbmr.1542

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN： 0884-0431            Impact factor:   6.741


× No keyword cloud information.
  14 in total

1.  Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.

Authors:  Jun Iwamoto; Mitsuyoshi Uzawa
Journal:  Clin Rheumatol       Date:  2014-11-01       Impact factor: 2.980

2.  Hip fracture trends in the United States, 2002 to 2015.

Authors:  E Michael Lewiecki; N C Wright; J R Curtis; E Siris; R F Gagel; K G Saag; A J Singer; P M Steven; R A Adler
Journal:  Osteoporos Int       Date:  2017-12-27       Impact factor: 4.507

Review 3.  Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday.

Authors:  Jordan C Villa; Arianna Gianakos; Joseph M Lane
Journal:  HSS J       Date:  2015-12-09

4.  Bisphosphonate drug holiday: who, when and how long.

Authors:  Dima L Diab; Nelson B Watts
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-06       Impact factor: 5.346

5.  Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study.

Authors:  N C Wright; P J Foster; A S Mudano; J A Melnick; E M Lewiecki; W J Shergy; J R Curtis; G R Cutter; M I Danila; M L Kilgore; E C Lewis; S L Morgan; D T Redden; A H Warriner; K G Saag
Journal:  Osteoporos Int       Date:  2017-05-24       Impact factor: 4.507

6.  Eleven years of experience with bisphosphonate plus alfacalcidol treatment in a man with osteogenesis imperfecta type I.

Authors:  Jun Iwamoto; Yoshihiro Sato; Mitsuyoshi Uzawa; Hideo Matsumoto
Journal:  Ther Clin Risk Manag       Date:  2012-12-28       Impact factor: 2.423

7.  The effects of the Korean reference value on the prevalence of osteoporosis and the prediction of fracture risk.

Authors:  Sungwha Lee; Moon-Gi Choi; Jaemyung Yu; Ohk-Hyun Ryu; Hyung Joon Yoo; Sung-Hee Ihm; Doo-Man Kim; Eun-Gyung Hong; Kyutae Park; Myungjin Choi; Hyunhee Choi
Journal:  BMC Musculoskelet Disord       Date:  2015-03-27       Impact factor: 2.362

8.  Natural history of incomplete atypical femoral fractures in patients after a prolonged and variable course of bisphosphonate therapy-a long-term radiological follow-up.

Authors:  M A Png; P C Mohan; J S B Koh; C Y Howe; T S Howe
Journal:  Osteoporos Int       Date:  2019-08-21       Impact factor: 4.507

9.  A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring.

Authors:  Brian McNabb; Eric Vittinghoff; Richard Eastell; Ann V Schwartz; Douglas C Bauer; Kristine Ensrud; Elizabeth Barrett-Connor; Dennis M Black
Journal:  J Clin Endocrinol Metab       Date:  2014-08-15       Impact factor: 5.958

10.  Evolution and etiopathogenesis of bisphosphonates induced osteonecrosis of the jaw.

Authors:  Vijay Kumar; Raman Kant Sinha
Journal:  N Am J Med Sci       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.